HuYON 007
Alternative Names: HuYON007; HuYON007 MultYbody™Latest Information Update: 19 Apr 2023
At a glance
- Originator JN Biosciences
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action TRAIL receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Apr 2023 Preclinical development is ongoing in USA (Parenteral) (JN Biosciences pipeline, April 2023)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 30 May 2017 HuYON 007 is available for licensing as of 30 May 2017. http://www.jn-bio.com/pipeline (JN Biosciences pipeline, May 2017)